Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

• DOI: 10.1200/po.20.00424
• Publication Date: 2021-04-06T19:58:41Z
• Authors: Edmond M. Kwan; Chao Dai; Heidi Fettke; Christine Hauser; Maria M. Docanto; Patricia Bukczynska; Nicole Ng; Siavash Foroughi; Lisa-Jane K. Graham; Kate Mahon; Winston Tan; Xiaohong Wang; Zhixin Zhao; Tiantian Zheng; Kemin Zhou; Jianjun Yu; Pan Du; Lisa G. Horvath; Shidong Jia; Manish Kohli; Arun A. Azad
• Keywords: Male; 0303 health sciences; PTEN Phosphohydrolase; DNA Fingerprinting; 3. Good health; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; 03 medical and health sciences; Humans; Prospective Studies; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Cell-Free Nucleic Acids; Proto-Oncogene Proteins c-akt; Signal Transduction

Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition PTEN-deficient mCRPC, we profiled pathway aberrations patients with mCRPC using a novel cfDNA assay optimized for CNV detection.